Bio-Reference Laboratories (BRLI) 34.69 $BRLI
Global Clinical Laboratory Services Market Report - Analysis, Technologies & Forecasts - Key Vendors: Bio-Reference Labs, DaVita Healthcare Partners, Laboratory Corp of America - Research and Markets
BusinessWire - Mon Apr 11, 4:59AM CDT
Research and Markets has announced the addition of the "Clinical Laboratory Services Market" report to their offering.
BRLI: 34.69 (+0.08)
Global In-Vitro Diagnostic Testing Services Market Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/ddpx6m/in_vitro) has announced the addition of the "In Vitro Diagnostic Testing Services Market Forecasts 2016 to 2019 - Global Version " report to their offering. Our facts. Your success. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. The only report in the world that forecasts Laboratory Tests Volumes and Retail Prices rather than sales of reagents and instruments. Detailed Market Forecasts provide Price, Volume and Revenue Forecasts individually broken out by year for Each Clinical Laboratory Department. Genomics technology drives industry growth but changes the nature of diagnostic services..... This is an impressive piece of work. Doug Buchanan, Managing Director and CEO BC Biomedical Laboratories Ltd. Its a market that just keeps on growing. A range of dynamic trends are pushing market growth and company valuations. Trends like: - Changing demographics - Emerging economies and global prosperity - Biotechnology advances in genetics - Pathogen evolution - Climate change - Globalization - Automation Separate forecasts for: - Clinical Chemistry - Microbiology - Hematology - Anatomic Pathology - Molecular Diagnostics Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. The Future of the Clinical Laboratory Companies Mentioned - 35 of the 80 Companies Featured - 23andme - Acibadem Labmed Laboratory - ACM Medical Laboratory - Adicon Clinical Laboratories, Inc - Aegis Sciences . - Agena Biosciences - Alere Inc - American Pathology Partners, Inc. - Ariosa Diagnostics - ARUP Laboratories, Inc. - Ascend Clinical, LLC - AstraZeneca - Atossa - Aurora Diagnostics, LLC - Biomnis (France) - Bio-Reference Laboratories, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - BP Lab - Caprion - Caris Life Sciences, Inc. - Centrex Clinical Laboratories, Inc. - Clarient, Inc. - Claritas Genomics - Claymon Biomnis Laboratories Ltd. - Clinical Reference Laboratory, Inc. - Clongen Laboratories LLC - CompuNet Clinical Laboratories, LLC - DiaCarta - Diagn?sticos da Am?rica (DASA) - DL Reference Laboratory - Enzo Biochem, Inc. - Epic Sciences - Exagen Diagnostics, Inc. - Eurofins - Foundation Medicine For more information visit http://www.researchandmarkets.com/research/ddpx6m/in_vitro
FMI: 20.63 (+0.11), ENZ: 5.85 (+0.29), BRLI: 34.69 (+0.08), ALR: 38.44 (-0.69), ARDX: 10.32 (+0.35)
North America Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/5jg3ps/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - North America Version " report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2016 to 2019 North America Version" Features - Data that analysts and planners can use - Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing - Make facilities planning decisions - Forecast demand for new testing regimes or technologies - Make research investment decisions Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. The Future of the Clinical Laboratory Companies Mentioned - Acibadem Labmed Laboratory - ACM Medical Laboratory - Adicon Clinical Laboratories, Inc. - Alere Inc - American Pathology Partners, Inc. - ARUP Laboratories, Inc. - Ascend Clinical, LLC - Aurora Diagnostics, LLC - Biomnis (France) - Bio-Reference Laboratories, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - BP Lab - Caris Life Sciences, Inc. - Centrex Clinical Laboratories, Inc. - Clarient, Inc. - Clongen Laboratories LLC - CompuNet Clinical Laboratories, LLC - Diagn?sticos da Am?rica (DASA) - DL Reference Laboratory - Enzo Biochem, Inc. - Exagen Diagnostics, Inc. - Genomic Health, Inc. - Genzyme Corporation - Gribbles Pathology - Integrated Regional Laboratories, Inc. - Predictive Biosciences, Inc. - Psychemedics Corp. - Rosetta Genomics Inc. - Signal Genetics LLC - Solstas Lab Partners - Sonic Healthcare Limited - Spectra Spectra Laboratories, Inc. - The Doctor's Laboratory (Sonic Healthcare U.K.) - Unilabs SA - Vira Cor-Ibt Laboratories For more information visit http://www.researchandmarkets.com/research/5jg3ps/clinical
PMD: 20.15 (-0.12), BRLI: 34.69 (+0.08), ALR: 38.44 (-0.69), ARDX: 10.32 (+0.35), GHDX: 26.67 (+0.20), ENZ: 5.85 (+0.29)
Asia Pacific Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019
M2 - Mon Jan 25, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/sx57w8/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - Asia Pacific Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 2.1 Market Participants 2.2 Market Segments 2.3 Industry Structure 2.4 Profiles of Key Companies 2.5 National and Regional Diversity 3. Market Trends 3.1 Factors Driving Growth 3.2 Factors Limiting Growth 3.3 Automation 3.4 Environment and Evolution 3.5 Diagnostic Technology Development 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Markets - Asia Pacific 6. The Future of the Clinical Laboratory Companies Mentioned - Acibadem Labmed Laboratory - ACM Medical Laboratory - Adicon Clinical Laboratories, Inc. - Alere Inc - American Pathology Partners, Inc. - ARUP Laboratories, Inc. - Ascend Clinical, LLC - Aurora Diagnostics, LLC - Biomnis (France) - Bio-Reference Laboratories, Inc. - Claymon Biomnis Laboratories Ltd. - Clinical Reference Laboratory, Inc. - Clongen Laboratories LLC - CompuNet Clinical Laboratories, LLC - Diagn?sticos da Am?rica (DASA) - DL Reference Laboratory - Enzo Biochem, Inc. - Exagen Diagnostics, Inc. - Genomic Health, Inc. - Genzyme Corporation - Laboratory Corporation of America - Lifelabs Medical Laboratory Services - Medicus Phillipines Inc. - MEDTOX Scientific, Inc. - Mid America Clinical Laboratories, LLC - Myriad Genetics, Inc. - Pathology Inc. - Rosetta Genomics Inc. - Signal Genetics LLC - Solstas Lab Partners - Sonic Healthcare Limited - Spectra Spectra Laboratories, Inc. - The Doctor's Laboratory (Sonic Healthcare U.K.) - Unilabs SA - Vira Cor-Ibt Laboratories For more information visit http://www.researchandmarkets.com/research/sx57w8/clinical
MYGN: 20.44 (+0.08), BRLI: 34.69 (+0.08), ALR: 38.44 (-0.69), ARDX: 10.32 (+0.35), GHDX: 26.67 (+0.20), ENZ: 5.85 (+0.29)
Europe Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019
M2 - Fri Jan 22, 9:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/qbs9gc/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - Europe Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Make investment decisions and valuations with confidence using the latest data. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 6. Country Markets - Europe 7. The Future of the Clinical Laboratory Companies Mentioned - Quest Diagnostics - Laboratory Corporation of America - Lifelabs Medical Laboratory Services - ACM Medical Laboratory - Spectra Spectra Laboratories, Inc. - Bio-Reference Laboratories, Inc. - Signal Genetics LLC - CompuNet Clinical Laboratories, LLC - Genzyme Corporation - Sonic Healthcare Limited - Exagen Diagnostics, Inc. - Clongen Laboratories LLC - Clinical Reference Laboratory, Inc. - Rosetta Genomics Inc. - Psychemedics Corp. - Aurora Diagnostics, LLC - DL Reference Laboratory - Myriad Genetics, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - Acibadem Labmed Laboratory - Claymon Biomnis Laboratories Ltd. - Biomnis (France) - The Doctor's Laboratory (Sonic Healthcare U.K.) - Unilabs SA - American Pathology Partners, Inc. - Centrex Clinical Laboratories, Inc. - Integrated Regional Laboratories, Inc. - Vira Cor-Ibt Laboratories - Clarient, Inc. - Genomic Health, Inc. - ARUP Laboratories, Inc. - MEDTOX Scientific, Inc. - Solstas Lab Partners - Predictive Biosciences, Inc. - Enzo Biochem, Inc. For more information visit http://www.researchandmarkets.com/research/qbs9gc/clinical
PMD: 20.15 (-0.12), MYGN: 20.44 (+0.08), BRLI: 34.69 (+0.08), ARDX: 10.32 (+0.35), GHDX: 26.67 (+0.20), ENZ: 5.85 (+0.29), DGX: 82.36 (-0.46)
United States Clinical Laboratory Services Market Report 2015
M2 - Wed Dec 16, 3:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/5fp5b5/clinical) has announced the addition of the "Clinical Laboratory Services Market" report to their offering. Clinical Laboratory Services Market, provides an in-depth market overview, a total market analysis, analysis by laboratory type, and by routine and specialty testing and a review of the latest trends driving growth. Revenues and forecasts, segment breakouts and market share presented are for the U.S. market, but international clinical lab service markets are estimated and forecasted in this report. Laboratory services are a key component of the healthcare system and an important part of the commercialization of in vitro diagnostic tests. It is estimated that approximately 80% of physician's diagnoses are a result of laboratory tests, and a fair number of these tests are sent to clinical lab service providers. There is constant pressure to reduce healthcare spending, and that in turn is shifting healthcare utilization in favor of the laboratory. This has not escaped the attention of major competitors who operate in the industry, and those planning to enter. Key market data provided includes: - The US Clinical Laboratry Market and Forecast - Markets for Tissue Pathology - Markets for Routine Chemistry Testing - Markets for Non-Tissue Molecular - Market for Toxicology/Drug Abuse Testing - European Market and Forecast - Asian Pacific Market and Forecast - Latin American Market and Forecast - Hospital, Physician and Independent Lab Statistics - Major Tests Performed by Clinical Lab Companies A competitive analysis of leading clinical laboratory providers includes: - Bio-Reference Laboratories - Da Vita Healthcare - Quest Diagnostics, Inc. - Laboratory Corporation of America (LabCorp) - Genomic Health - Genoptix - Sonic Healthcare - Myriad Genetics - Genzyme Corporation - Clarient, Inc. - Spectra Laboratories Key Topics Covered: - Executive Summary - Industry Overview - Issues And Trends In The Clinical Laboratory Industry - Leading Market Participants - Market Trends And Summary - List Of Major Companies For more information visit http://www.researchandmarkets.com/research/5fp5b5/clinical
MYGN: 20.44 (+0.08), BRLI: 34.69 (+0.08), DGX: 82.36 (-0.46), GHDX: 26.67 (+0.20)
Global IVD Procedure Volumes and Pricing Analysis Report - Profiles Include Siemens, Roche & Gen-Probe, Inc
M2 - Mon Dec 14, 7:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/mpftmx/ivd_procedure) has announced the addition of the "IVD Procedure Volumes and Pricing Analysis" report to their offering. This Kalorama Information report, IVD Procedure Volumes and Pricing Analysis, takes an informative look at worldwide procedure volumes for IVD tests. The report provides global 2014 sales of equipment, reagents and other products related to in vitro diagnostic tests. Market estimates for each major market segment represent global revenues and are expressed in current dollars. Segments covered include: - Point-of-Care (OTC Total, Glucose, Pregnancy/ Ovulation, Other, Professional Total, Glucose, Infectious Disease, Critical Care, Other) - Molecular (Infectious Disease [inc. molecular tests for HIV, Hepatitis, STDs, HAI, Respiratory, Other], Oncology, Inherited Disease, Other) - HematologyCoagulation (PT, PTT) - Microbiology (Automated Panels, Manual Panels, Blood Culture, Chromogenic Media) - Blood BankingCore lab (General Chemistries, Blood Gas Analyzers, Urinalysis, Immunoassays Infectious Disease, Cardiac Markers, Diabetes/HbA1c, Autoimmune) - Histology/Cytology (Pap, Non-Pap, Image Cytometry, Flow Cytometry, ISH, IHC, CTCs) This report, IVD Procedure Volumes and Pricing Analysis is a one of a kind reprot that demonstrates to readers which companies are performing what share of IVD procedures in the market. The following IVD leaders are profiled and their procedure volumes are analyzed in this report: - Roche - Siemens - Spectra Laboratories - Sysmex Corp. - Thermo Fisher Scientific - Abbott Laboratories - ALERE - ArkrayBeckman Coulter, Inc. - Danaher - Becton - Dickinson & Co. - bioMerieux, Inc - Bio-RAD Laboratories, Inc - Bio-Reference Laboratories - Genoptix, Inc. - Novartis - Gen-Probe, Inc - Hologic, Inc - Horiba Medical - Instrumentation Laboratory - Laboratory Corporation of America - Myriad Genetics - Ortho Clinical Diagnostics - Qiagen - Quest Diagnostics - Radiometer A/S - Clarient, Inc. - GE Healthcare - Danaher Corp - DaVita, Inc. Report Structure: ONE: EXECUTIVE SUMMARY TWO: INTRODUCTION THREE: POINT-OF-CARE TESTS FOUR: CORE LABORATORY TESTS FIVE: MOLECULAR ASSAYS SIX: HEMATOLOGY SEVEN: COAGULATION EIGHT: MICROBIOLOGY NINE: TESTS USED IN BLOOD BANKING TEN: HISTOLOGY AND CYTOLOGY ELEVEN: PROFILES OF KEY PLAYERS APPENDIX: COMPANY DIRECTORY For more information visit http://www.researchandmarkets.com/research/mp..._procedure
ABT: 42.30 (+0.28), MYGN: 20.44 (+0.08), BRLI: 34.69 (+0.08), DHR: 81.44 (+0.03), DVA: 64.19 (-0.44), DGX: 82.36 (-0.46), HOLX: 38.46 (+0.04), NVS: 78.27 (-0.50)
OPKO Announces Third Quarter Financial and Operating Results
BusinessWire - Mon Nov 09, 3:13PM CST
--Closed Acquisition of Bio-Reference Laboratories on August 20, 2015
BRLI: 34.69 (+0.08), OPK: 9.29 (+0.19)
Global Clinical Laboratory Tests Market Analysis 2015 - Forecasts To 2020 for the $148 Billion Industry
M2 - Wed Nov 04, 4:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/kp9dqc/clinical) has announced the addition of the "Clinical Laboratory Tests Market Analysis By Product And Segment - Forecasts To 2020" report to their offering. The global market for clinical laboratory is expected to reach USD 148.82 billion by 2020, growing at an estimated CAGR of 6.8% from 2014 to 2020 Growing prevalence of chronic diseases and the development of novel laboratory testing methodologies is expected to drive the clinical laboratory tests market through to 2020. Due to the fact that results from clinical laboratory tests are the fundamental basis upon which medical practitioners and healthcare providers form their diagnosis and prognosis for the prevention and treatment for a range of diseases, clinical laboratory tests are critical to the global healthcare and medical fraternity. A growing global prevalence of medical conditions such as diabetes, obesity and other metabolic abnormalities coupled with increasing patient awareness levels is expected to boost market growth during the forecast period. For the purpose of this study, the report has segmented the clinical laboratory tests market on the basis of test type, laboratory type - Global Clinical Laboratory Tests, Test Type Outlook (Revenue, USD Billion, 2012 - 2020) - Complete Blood Count Market, by Laboratory Type - HGB/HCT Tests Market, by Laboratory Type - Basic Metabolic Panel Market, by Laboratory Type - BUN Creatinine Tests Market, by Laboratory Type - Electrolytes Testing Market, by Laboratory Type - HbA1c Tests Market, by Laboratory Type - Comprehensive Metabolic Panel Market, by Laboratory Type - Liver Panel Tests Market, by Laboratory Type - Renal Panel Tests Market, by Laboratory Type - Lipid Panel Tests Market, by Laboratory Type - Clinical Laboratory Tests Regional Outlook (Revenue, USD Billion, 2012 - 2020) Competitive Landscape - Siemens - Charles River Laboratories - Quest Diagnostics Inc. - Bioscientia Healthcare - Sonic Healthcare Limited - Abbott Laboratories - Bio-Reference Laboratories - Labco S.A. - Healtscope Limited - Spectra Laboratories - Laboratory corporation of America Holdings (Labcorp) - ARUP Laboratories - Genoptix Medical Laboratory - Qiagen - Clarient Inc. - Genzyme Corporation For more information visit http://www.researchandmarkets.com/research/kp9dqc/clinical
ABT: 42.30 (+0.28), BRLI: 34.69 (+0.08), DGX: 82.36 (-0.46), LH: 136.13 (-0.80)
Shares of BRLI Down 7.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Aug 25, 11:22AM CDT
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on August 7th, 2015 at $37.24. In approximately 3 weeks, Bio-Reference Labs has returned 7.06% as of today's recent price of $34.61.
BRLI: 34.69 (+0.08)
OPKO buys Bio-Reference Laboratories
M2 - Fri Aug 21, 6:06AM CDT
Biopharmaceutical company OPKO Health (NYSE:OPK) revealed on Thursday that it has completed the acquisition of Bio-Reference Laboratories (NasdaqGS:BRLI).
BRLI: 34.69 (+0.08), OPK: 9.29 (+0.19)
Innospec Set to Join the S&P SmallCap 600
PR Newswire - Thu Aug 20, 5:38PM CDT
Innospec Inc. (NASD:IOSP) will replace Bio-Reference Laboratories Inc. (NASD:BRLI) in the S&P SmallCap 600 after the close of trading on Friday, August 21. OPKO Health Inc. (NYSE:OPK) is acquiring Bio-Reference Laboratories in a deal that closed today.
BRLI: 34.69 (+0.08), OPK: 9.29 (+0.19), IOSP: 59.02 (-0.26), MHFI: 107.92 (+1.16)
OPKO Announces Second Quarter Operating and Financial Results
BusinessWire - Wed Aug 05, 3:00PM CDT
--Acquired EirGen Pharma, A Growing, Profitable Specialty Pharmaceutical Developer and Manufacturer
BRLI: 34.69 (+0.08), OPK: 9.29 (+0.19)
Shares of BRLI Up 22.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Aug 04, 5:07PM CDT
SmarTrend identified an Uptrend for Bio-Reference Labs (NASDAQ:BRLI) on March 24th, 2015 at $35.80. In approximately 4 months, Bio-Reference Labs has returned 22.78% as of today's recent price of $43.95.
BRLI: 34.69 (+0.08)
Bio-Reference Labs Has Returned 25.9% Since SmarTrend Recommendation (BRLI)
Comtex SmarTrend(R) - Tue Jul 28, 12:01PM CDT
SmarTrend identified an Uptrend for Bio-Reference Labs (NASDAQ:BRLI) on March 24th, 2015 at $35.80. In approximately 4 months, Bio-Reference Labs has returned 25.90% as of today's recent price of $45.06.
BRLI: 34.69 (+0.08)
The Market for Prenatal, Newborn and Carrier Genetic Testing 2015
M2 - Fri Jul 24, 4:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h7ccfb/the_market_for) has announced the addition of the "The Market for Prenatal, Newborn and Carrier Genetic Testing" report to their offering. The Market for Prenatal, Newborn and Carrier Genetic Testing discusses the technologies and tests used in chromosomal analysis and in the diagnosis of inherited disorders and the detection of carriers of inherited diseases. The growing number of genetic tests has been made possible by advances in technology, including advances in chromosomal analysis - from traditional karyotyping to fluorescence in situ hybridization (FISH), and then to chromosomal microarrays and next generation sequencing. Detection of single gene mutations has been made possible with FISH and polymerase chain reaction (PCR) technology, and is moving into even new possibilities with sequencing based tests that can evaluate large numbers of genes simultaneously. The recent introduction of noninvasive prenatal testing (NIPT) has made it possible to perform prenatal screening of fetuses without the need for invasive procedures. The growing global genetic testing laboratory services market is discussed, including: - Carrier testing - Prenatal testing - Newborn screening - Neonatal/pediatric testing - Testing for adult onset genetic disorders The technologies used for newborn screening discussed in the report include: - Karyotyping - Fluorescence in situ Hybridization - Chromosomal Microarrays - Polymerase Chain Reaction and Other Nucleic Acid Amplification Technologies - DNA Sequencing - Mass Spectrometry - Conventional versus Non-Invasive Prenatal Testing Inherited disease testing was already a large market, but the potential for rapid growth has attracted companies and investors. The report highlights recent activities in this rapidly evolving market. Leading competitors and product developers are listed in the manufacturer profiles. The profiled companies include: Partial List - 23andMe, Inc. - AB SCIEX (A Danaher Corporation Company) - Abbott Laboratories - Affymetrix, Inc. - Agena Bioscience Inc. - Agilent Technologies Inc. - Ambry Genetics Corp. - ARUP Laboratories - Astra Biotech GmbH - Asuragen, Inc. - Athena Diagnostics, Inc. (A Quest Diagnostics Business) - AutoGenomics, Inc. - Berry Genomics Co., Ltd. - BGI-Shenzhen - Bio-Rad Laboratories, Inc. - Bio-Reference Laboratories, Inc. (BRLI) - Centogene AG - Chromsystems Instruments & Chemicals GmbH - Claritas Genomics, Inc. - Color Genomics, Inc. - CombiMatrix Corporation - Counsyl, Inc. - Courtagen Life Sciences, Inc. - GenapSys - Gene by Gene, Ltd. - Genection, Inc. (An Invivoscribe Company) - GeneDx - GenePeeks, Inc. - Genesis Genetics - Genetadi Biotech S.L. - Genetic Technologies Limited / Phenogen Sciences, Inc. (U.S. Division) - GenMark Diagnostics, Inc. - Genoma Group - Genomed AG - GenPath / GenPath Women's Health For more information visit http://www.researchandmarkets.com/research/h7...market_for
GNMK: 8.63 (+0.11), ABT: 42.30 (+0.28), AGMX: (), BRLI: 34.69 (+0.08), A: 46.99 (+0.01), CBMX: 2.97 (-0.08), AFFX: 14.01 (+0.02), ATHN: 123.13 (+0.70)
Uptrend Call Working As Bio-Reference Labs Stock Rises 23.6% (BRLI)
Comtex SmarTrend(R) - Tue Jul 21, 10:42AM CDT
SmarTrend identified an Uptrend for Bio-Reference Labs (NASDAQ:BRLI) on March 24th, 2015 at $35.80. In approximately 4 months, Bio-Reference Labs has returned 23.56% as of today's recent price of $44.23.
BRLI: 34.69 (+0.08)
Analyst Scanner on Medical Laboratories and Research Equities -- Thermo Fisher Scientific, Quest Diagnostics, Exact Sciences, VWR Corp., and Bio-Reference Laboratories
PR Newswire - Tue Jul 21, 8:05AM CDT
Equity Research Institute has initiated coverage on the following equities: Thermo Fisher Scientific Inc. (NYSE: TMO), Quest Diagnostics Inc. (NYSE: DGX), Exact Sciences Corporation (NASDAQ: EXAS), VWR Corporation (NASDAQ: VWR), and Bio-Reference Laboratories Inc. (NASDAQ: BRLI). Free research report on Thermo Fisher Scientific can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=TMO On Monday, July 20, 2015, the NASDAQ Composite ended at 5,218.86, up 0.17%, the Dow Jones Industrial Average advanced 0.08%, to finish the day at 18,100.41, and the S&P 500 closed at 2,128.28, up 0.08%. The losses were broad based as five out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
BRLI: 34.69 (+0.08), VWR: 27.75 (-0.16), TMO: 150.95 (-1.24), DGX: 82.36 (-0.46), EXAS: 18.19 (-0.28)
Research and Markets: Pharma Vital Signs: The Analyst's Perspective - June 2015 Issue
BusinessWire - Wed Jul 15, 7:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qv6c38/vital_signs_the) has announced the addition of the "Vital Signs - The Analyst's Perspective - June 2015 Issue" report to their offering.
BRLI: 34.69 (+0.08), OPK: 9.29 (+0.19)
Pharma Vital Signs: The Analyst's Perspective - June 2015 Issue
M2 - Wed Jul 15, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qs49hj/vital_signs_the) has announced the addition of the "Vital Signs - The Analyst's Perspective - June 2015 Issue" report to their offering. This issue of Vital Signs, released in July 2015, discusses Affmetrix's acquisition of Eureka Genomics, OPKO Health's acquisition of Bio-Reference Laboratories, CVS Health's acquisition of Target's in-store pharmacies and clinics, and Thermo Fisher Scientific's acquisition of Alfa Aesar. Affymetrix acquired all the assets of Eureka Genomics, including its high throughput crop and animal genotyping technology, for $15 million. Eureka's assays use next-generation sequencing (NGS), a rapidly growing technology utilized in various applications. As part of the acquisition, Affymetrix has also signed a multi-year contract to offer Eureka's technologies to Zoetis for use in animal genetics. Zoetis is a subsidiary of Pfizer and is the largest producer of medicine and vaccinations for pets and livestock. Molecular testing is a rapidly growing area in healthcare. The fields of application are now extending beyond life sciences and clinical diagnostics to other areas. Next-generation sequencing technologies are rapidly being employed in animal testing for testing pathogens. this is an emerging segment that requires a lot of trait management and traceability. Gene testing for animal health and cattle management has been relatively expensive, and technologies to facilitate broader genotyping of low-density traits, such as parentage, have been limited. Eureka Genomics is a developer of cost-effective high, medium, and low assays that use NGS technology for signal read out. these assays can enable the detection of several genetic markers that have high prevalence in crop and animal genomic testing. Eureka also provides NGS and genotyping services to government agencies, universities, research centers, and agriculture companies. Its assays can be applied to detection of copy number variation (CNV), methylation, and single nucleotide polymorphisms (SNPs). the information is compatible with any dNA or rNA from any organism, despite the incompleteness of genome information. this makes the technology very unique and powerful, answering several questions by combining discriminatory power of hybridization and ligation. Furthermore, Eureka's assays are NGS instrument agnostic and can be easily adapted to any modifications made in the instruments, such as upgrading, data generation, or even change of instrument. Affymetrix has a strong presence with its product offerings for microarrays, polymerase chain reaction (PCR), flow cytometry, and sample purification. Given its market leadership in the microarray market, a substantial amount of customers use Affymetrix's products. the area of animal testing and agrigenomics is not new to Affymetrix, as it sells its Axiom Genotyping solutions in this space. reports also reveal that Affymetrix's customers have demanded a low-cost, effective solution focused on genetic variant panels for high-volume testing. The effect of the symbiotic relationship can be sensed over time. through this acquisition, Affymetrix can extend its business to a new business unit catering to the agrigenomics space. As a result, its customers can now support more applications, and Affymetrix can also serve new customers with a greater bandwidth of solutions. The company has also employed Eureka's assays and technologies with Zoetis, which is one of the largest animal health companies. The acquisition has already bolstered Affymetrix's presence in the cattle and animal health sector. In looking at Affymetrix's acquisitions in the past, the company made its last acquisition in 2012, acquiring eBioscience to expand into flow cytometry antibodies and strengthen its offerings in the reagent segment. Strengthening its current product line and expanding its customer base has been Affymetrix's long-term strategy since 2008. Key Topics Covered: 1. Affymetrix Acquires Eureka Genomics for $15 Million 2. OPKO Health, Inc. Acquires Bio-Reference Laboratories, Inc. for $1.47 Billion in Stock 3. Target Signs the Dotted Line Facilitating CVS Health to Acquire its In-store Pharmacies and Clinics 4. Thermo Fisher Scientific Acquires Alfa Aesar, Further Consolidating Life Science Chemicals Market Companies Mentioned - Affmetrix - Alfa Aesar - Axiom Genotype - Bio-Reference Laboratories - CVS Health - Eureka Genomics - OPKO Health, Inc. - Pfizer - Target - Thermo Fisher Scientific - Zoetis For more information visit http://www.researchandmarkets.com/research/qs..._signs_the
BRLI: 34.69 (+0.08), OPK: 9.29 (+0.19)
Global Clinical Laboratory Services Market Report - Analysis, Technologies & Forecasts - Key Vendors: Bio-Reference Labs, DaVita Healthcare Partners, Laboratory Corp of America - Research and Markets
BusinessWire - Mon Apr 11, 4:59AM CDT
Research and Markets has announced the addition of the "Clinical Laboratory Services Market" report to their offering.
BRLI: 34.69 (+0.08)
Global In-Vitro Diagnostic Testing Services Market Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/ddpx6m/in_vitro) has announced the addition of the "In Vitro Diagnostic Testing Services Market Forecasts 2016 to 2019 - Global Version " report to their offering. Our facts. Your success. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. The only report in the world that forecasts Laboratory Tests Volumes and Retail Prices rather than sales of reagents and instruments. Detailed Market Forecasts provide Price, Volume and Revenue Forecasts individually broken out by year for Each Clinical Laboratory Department. Genomics technology drives industry growth but changes the nature of diagnostic services..... This is an impressive piece of work. Doug Buchanan, Managing Director and CEO BC Biomedical Laboratories Ltd. Its a market that just keeps on growing. A range of dynamic trends are pushing market growth and company valuations. Trends like: - Changing demographics - Emerging economies and global prosperity - Biotechnology advances in genetics - Pathogen evolution - Climate change - Globalization - Automation Separate forecasts for: - Clinical Chemistry - Microbiology - Hematology - Anatomic Pathology - Molecular Diagnostics Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. The Future of the Clinical Laboratory Companies Mentioned - 35 of the 80 Companies Featured - 23andme - Acibadem Labmed Laboratory - ACM Medical Laboratory - Adicon Clinical Laboratories, Inc - Aegis Sciences . - Agena Biosciences - Alere Inc - American Pathology Partners, Inc. - Ariosa Diagnostics - ARUP Laboratories, Inc. - Ascend Clinical, LLC - AstraZeneca - Atossa - Aurora Diagnostics, LLC - Biomnis (France) - Bio-Reference Laboratories, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - BP Lab - Caprion - Caris Life Sciences, Inc. - Centrex Clinical Laboratories, Inc. - Clarient, Inc. - Claritas Genomics - Claymon Biomnis Laboratories Ltd. - Clinical Reference Laboratory, Inc. - Clongen Laboratories LLC - CompuNet Clinical Laboratories, LLC - DiaCarta - Diagn?sticos da Am?rica (DASA) - DL Reference Laboratory - Enzo Biochem, Inc. - Epic Sciences - Exagen Diagnostics, Inc. - Eurofins - Foundation Medicine For more information visit http://www.researchandmarkets.com/research/ddpx6m/in_vitro
FMI: 20.63 (+0.11), ENZ: 5.85 (+0.29), BRLI: 34.69 (+0.08), ALR: 38.44 (-0.69), ARDX: 10.32 (+0.35)
North America Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/5jg3ps/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - North America Version " report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2016 to 2019 North America Version" Features - Data that analysts and planners can use - Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing - Make facilities planning decisions - Forecast demand for new testing regimes or technologies - Make research investment decisions Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. The Future of the Clinical Laboratory Companies Mentioned - Acibadem Labmed Laboratory - ACM Medical Laboratory - Adicon Clinical Laboratories, Inc. - Alere Inc - American Pathology Partners, Inc. - ARUP Laboratories, Inc. - Ascend Clinical, LLC - Aurora Diagnostics, LLC - Biomnis (France) - Bio-Reference Laboratories, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - BP Lab - Caris Life Sciences, Inc. - Centrex Clinical Laboratories, Inc. - Clarient, Inc. - Clongen Laboratories LLC - CompuNet Clinical Laboratories, LLC - Diagn?sticos da Am?rica (DASA) - DL Reference Laboratory - Enzo Biochem, Inc. - Exagen Diagnostics, Inc. - Genomic Health, Inc. - Genzyme Corporation - Gribbles Pathology - Integrated Regional Laboratories, Inc. - Predictive Biosciences, Inc. - Psychemedics Corp. - Rosetta Genomics Inc. - Signal Genetics LLC - Solstas Lab Partners - Sonic Healthcare Limited - Spectra Spectra Laboratories, Inc. - The Doctor's Laboratory (Sonic Healthcare U.K.) - Unilabs SA - Vira Cor-Ibt Laboratories For more information visit http://www.researchandmarkets.com/research/5jg3ps/clinical
PMD: 20.15 (-0.12), BRLI: 34.69 (+0.08), ALR: 38.44 (-0.69), ARDX: 10.32 (+0.35), GHDX: 26.67 (+0.20), ENZ: 5.85 (+0.29)
Asia Pacific Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019
M2 - Mon Jan 25, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/sx57w8/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - Asia Pacific Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 2.1 Market Participants 2.2 Market Segments 2.3 Industry Structure 2.4 Profiles of Key Companies 2.5 National and Regional Diversity 3. Market Trends 3.1 Factors Driving Growth 3.2 Factors Limiting Growth 3.3 Automation 3.4 Environment and Evolution 3.5 Diagnostic Technology Development 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Markets - Asia Pacific 6. The Future of the Clinical Laboratory Companies Mentioned - Acibadem Labmed Laboratory - ACM Medical Laboratory - Adicon Clinical Laboratories, Inc. - Alere Inc - American Pathology Partners, Inc. - ARUP Laboratories, Inc. - Ascend Clinical, LLC - Aurora Diagnostics, LLC - Biomnis (France) - Bio-Reference Laboratories, Inc. - Claymon Biomnis Laboratories Ltd. - Clinical Reference Laboratory, Inc. - Clongen Laboratories LLC - CompuNet Clinical Laboratories, LLC - Diagn?sticos da Am?rica (DASA) - DL Reference Laboratory - Enzo Biochem, Inc. - Exagen Diagnostics, Inc. - Genomic Health, Inc. - Genzyme Corporation - Laboratory Corporation of America - Lifelabs Medical Laboratory Services - Medicus Phillipines Inc. - MEDTOX Scientific, Inc. - Mid America Clinical Laboratories, LLC - Myriad Genetics, Inc. - Pathology Inc. - Rosetta Genomics Inc. - Signal Genetics LLC - Solstas Lab Partners - Sonic Healthcare Limited - Spectra Spectra Laboratories, Inc. - The Doctor's Laboratory (Sonic Healthcare U.K.) - Unilabs SA - Vira Cor-Ibt Laboratories For more information visit http://www.researchandmarkets.com/research/sx57w8/clinical
MYGN: 20.44 (+0.08), BRLI: 34.69 (+0.08), ALR: 38.44 (-0.69), ARDX: 10.32 (+0.35), GHDX: 26.67 (+0.20), ENZ: 5.85 (+0.29)
Europe Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019
M2 - Fri Jan 22, 9:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/qbs9gc/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - Europe Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Make investment decisions and valuations with confidence using the latest data. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 6. Country Markets - Europe 7. The Future of the Clinical Laboratory Companies Mentioned - Quest Diagnostics - Laboratory Corporation of America - Lifelabs Medical Laboratory Services - ACM Medical Laboratory - Spectra Spectra Laboratories, Inc. - Bio-Reference Laboratories, Inc. - Signal Genetics LLC - CompuNet Clinical Laboratories, LLC - Genzyme Corporation - Sonic Healthcare Limited - Exagen Diagnostics, Inc. - Clongen Laboratories LLC - Clinical Reference Laboratory, Inc. - Rosetta Genomics Inc. - Psychemedics Corp. - Aurora Diagnostics, LLC - DL Reference Laboratory - Myriad Genetics, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - Acibadem Labmed Laboratory - Claymon Biomnis Laboratories Ltd. - Biomnis (France) - The Doctor's Laboratory (Sonic Healthcare U.K.) - Unilabs SA - American Pathology Partners, Inc. - Centrex Clinical Laboratories, Inc. - Integrated Regional Laboratories, Inc. - Vira Cor-Ibt Laboratories - Clarient, Inc. - Genomic Health, Inc. - ARUP Laboratories, Inc. - MEDTOX Scientific, Inc. - Solstas Lab Partners - Predictive Biosciences, Inc. - Enzo Biochem, Inc. For more information visit http://www.researchandmarkets.com/research/qbs9gc/clinical
PMD: 20.15 (-0.12), MYGN: 20.44 (+0.08), BRLI: 34.69 (+0.08), ARDX: 10.32 (+0.35), GHDX: 26.67 (+0.20), ENZ: 5.85 (+0.29), DGX: 82.36 (-0.46)
United States Clinical Laboratory Services Market Report 2015
M2 - Wed Dec 16, 3:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/5fp5b5/clinical) has announced the addition of the "Clinical Laboratory Services Market" report to their offering. Clinical Laboratory Services Market, provides an in-depth market overview, a total market analysis, analysis by laboratory type, and by routine and specialty testing and a review of the latest trends driving growth. Revenues and forecasts, segment breakouts and market share presented are for the U.S. market, but international clinical lab service markets are estimated and forecasted in this report. Laboratory services are a key component of the healthcare system and an important part of the commercialization of in vitro diagnostic tests. It is estimated that approximately 80% of physician's diagnoses are a result of laboratory tests, and a fair number of these tests are sent to clinical lab service providers. There is constant pressure to reduce healthcare spending, and that in turn is shifting healthcare utilization in favor of the laboratory. This has not escaped the attention of major competitors who operate in the industry, and those planning to enter. Key market data provided includes: - The US Clinical Laboratry Market and Forecast - Markets for Tissue Pathology - Markets for Routine Chemistry Testing - Markets for Non-Tissue Molecular - Market for Toxicology/Drug Abuse Testing - European Market and Forecast - Asian Pacific Market and Forecast - Latin American Market and Forecast - Hospital, Physician and Independent Lab Statistics - Major Tests Performed by Clinical Lab Companies A competitive analysis of leading clinical laboratory providers includes: - Bio-Reference Laboratories - Da Vita Healthcare - Quest Diagnostics, Inc. - Laboratory Corporation of America (LabCorp) - Genomic Health - Genoptix - Sonic Healthcare - Myriad Genetics - Genzyme Corporation - Clarient, Inc. - Spectra Laboratories Key Topics Covered: - Executive Summary - Industry Overview - Issues And Trends In The Clinical Laboratory Industry - Leading Market Participants - Market Trends And Summary - List Of Major Companies For more information visit http://www.researchandmarkets.com/research/5fp5b5/clinical
MYGN: 20.44 (+0.08), BRLI: 34.69 (+0.08), DGX: 82.36 (-0.46), GHDX: 26.67 (+0.20)
Global IVD Procedure Volumes and Pricing Analysis Report - Profiles Include Siemens, Roche & Gen-Probe, Inc
M2 - Mon Dec 14, 7:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/mpftmx/ivd_procedure) has announced the addition of the "IVD Procedure Volumes and Pricing Analysis" report to their offering. This Kalorama Information report, IVD Procedure Volumes and Pricing Analysis, takes an informative look at worldwide procedure volumes for IVD tests. The report provides global 2014 sales of equipment, reagents and other products related to in vitro diagnostic tests. Market estimates for each major market segment represent global revenues and are expressed in current dollars. Segments covered include: - Point-of-Care (OTC Total, Glucose, Pregnancy/ Ovulation, Other, Professional Total, Glucose, Infectious Disease, Critical Care, Other) - Molecular (Infectious Disease [inc. molecular tests for HIV, Hepatitis, STDs, HAI, Respiratory, Other], Oncology, Inherited Disease, Other) - HematologyCoagulation (PT, PTT) - Microbiology (Automated Panels, Manual Panels, Blood Culture, Chromogenic Media) - Blood BankingCore lab (General Chemistries, Blood Gas Analyzers, Urinalysis, Immunoassays Infectious Disease, Cardiac Markers, Diabetes/HbA1c, Autoimmune) - Histology/Cytology (Pap, Non-Pap, Image Cytometry, Flow Cytometry, ISH, IHC, CTCs) This report, IVD Procedure Volumes and Pricing Analysis is a one of a kind reprot that demonstrates to readers which companies are performing what share of IVD procedures in the market. The following IVD leaders are profiled and their procedure volumes are analyzed in this report: - Roche - Siemens - Spectra Laboratories - Sysmex Corp. - Thermo Fisher Scientific - Abbott Laboratories - ALERE - ArkrayBeckman Coulter, Inc. - Danaher - Becton - Dickinson & Co. - bioMerieux, Inc - Bio-RAD Laboratories, Inc - Bio-Reference Laboratories - Genoptix, Inc. - Novartis - Gen-Probe, Inc - Hologic, Inc - Horiba Medical - Instrumentation Laboratory - Laboratory Corporation of America - Myriad Genetics - Ortho Clinical Diagnostics - Qiagen - Quest Diagnostics - Radiometer A/S - Clarient, Inc. - GE Healthcare - Danaher Corp - DaVita, Inc. Report Structure: ONE: EXECUTIVE SUMMARY TWO: INTRODUCTION THREE: POINT-OF-CARE TESTS FOUR: CORE LABORATORY TESTS FIVE: MOLECULAR ASSAYS SIX: HEMATOLOGY SEVEN: COAGULATION EIGHT: MICROBIOLOGY NINE: TESTS USED IN BLOOD BANKING TEN: HISTOLOGY AND CYTOLOGY ELEVEN: PROFILES OF KEY PLAYERS APPENDIX: COMPANY DIRECTORY For more information visit http://www.researchandmarkets.com/research/mp..._procedure
ABT: 42.30 (+0.28), MYGN: 20.44 (+0.08), BRLI: 34.69 (+0.08), DHR: 81.44 (+0.03), DVA: 64.19 (-0.44), DGX: 82.36 (-0.46), HOLX: 38.46 (+0.04), NVS: 78.27 (-0.50)
OPKO Announces Third Quarter Financial and Operating Results
BusinessWire - Mon Nov 09, 3:13PM CST
--Closed Acquisition of Bio-Reference Laboratories on August 20, 2015
BRLI: 34.69 (+0.08), OPK: 9.29 (+0.19)
Global Clinical Laboratory Tests Market Analysis 2015 - Forecasts To 2020 for the $148 Billion Industry
M2 - Wed Nov 04, 4:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/kp9dqc/clinical) has announced the addition of the "Clinical Laboratory Tests Market Analysis By Product And Segment - Forecasts To 2020" report to their offering. The global market for clinical laboratory is expected to reach USD 148.82 billion by 2020, growing at an estimated CAGR of 6.8% from 2014 to 2020 Growing prevalence of chronic diseases and the development of novel laboratory testing methodologies is expected to drive the clinical laboratory tests market through to 2020. Due to the fact that results from clinical laboratory tests are the fundamental basis upon which medical practitioners and healthcare providers form their diagnosis and prognosis for the prevention and treatment for a range of diseases, clinical laboratory tests are critical to the global healthcare and medical fraternity. A growing global prevalence of medical conditions such as diabetes, obesity and other metabolic abnormalities coupled with increasing patient awareness levels is expected to boost market growth during the forecast period. For the purpose of this study, the report has segmented the clinical laboratory tests market on the basis of test type, laboratory type - Global Clinical Laboratory Tests, Test Type Outlook (Revenue, USD Billion, 2012 - 2020) - Complete Blood Count Market, by Laboratory Type - HGB/HCT Tests Market, by Laboratory Type - Basic Metabolic Panel Market, by Laboratory Type - BUN Creatinine Tests Market, by Laboratory Type - Electrolytes Testing Market, by Laboratory Type - HbA1c Tests Market, by Laboratory Type - Comprehensive Metabolic Panel Market, by Laboratory Type - Liver Panel Tests Market, by Laboratory Type - Renal Panel Tests Market, by Laboratory Type - Lipid Panel Tests Market, by Laboratory Type - Clinical Laboratory Tests Regional Outlook (Revenue, USD Billion, 2012 - 2020) Competitive Landscape - Siemens - Charles River Laboratories - Quest Diagnostics Inc. - Bioscientia Healthcare - Sonic Healthcare Limited - Abbott Laboratories - Bio-Reference Laboratories - Labco S.A. - Healtscope Limited - Spectra Laboratories - Laboratory corporation of America Holdings (Labcorp) - ARUP Laboratories - Genoptix Medical Laboratory - Qiagen - Clarient Inc. - Genzyme Corporation For more information visit http://www.researchandmarkets.com/research/kp9dqc/clinical
ABT: 42.30 (+0.28), BRLI: 34.69 (+0.08), DGX: 82.36 (-0.46), LH: 136.13 (-0.80)
Shares of BRLI Down 7.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Aug 25, 11:22AM CDT
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on August 7th, 2015 at $37.24. In approximately 3 weeks, Bio-Reference Labs has returned 7.06% as of today's recent price of $34.61.
BRLI: 34.69 (+0.08)
OPKO buys Bio-Reference Laboratories
M2 - Fri Aug 21, 6:06AM CDT
Biopharmaceutical company OPKO Health (NYSE:OPK) revealed on Thursday that it has completed the acquisition of Bio-Reference Laboratories (NasdaqGS:BRLI).
BRLI: 34.69 (+0.08), OPK: 9.29 (+0.19)
Innospec Set to Join the S&P SmallCap 600
PR Newswire - Thu Aug 20, 5:38PM CDT
Innospec Inc. (NASD:IOSP) will replace Bio-Reference Laboratories Inc. (NASD:BRLI) in the S&P SmallCap 600 after the close of trading on Friday, August 21. OPKO Health Inc. (NYSE:OPK) is acquiring Bio-Reference Laboratories in a deal that closed today.
BRLI: 34.69 (+0.08), OPK: 9.29 (+0.19), IOSP: 59.02 (-0.26), MHFI: 107.92 (+1.16)
OPKO Announces Second Quarter Operating and Financial Results
BusinessWire - Wed Aug 05, 3:00PM CDT
--Acquired EirGen Pharma, A Growing, Profitable Specialty Pharmaceutical Developer and Manufacturer
BRLI: 34.69 (+0.08), OPK: 9.29 (+0.19)
Shares of BRLI Up 22.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Aug 04, 5:07PM CDT
SmarTrend identified an Uptrend for Bio-Reference Labs (NASDAQ:BRLI) on March 24th, 2015 at $35.80. In approximately 4 months, Bio-Reference Labs has returned 22.78% as of today's recent price of $43.95.
BRLI: 34.69 (+0.08)
Bio-Reference Labs Has Returned 25.9% Since SmarTrend Recommendation (BRLI)
Comtex SmarTrend(R) - Tue Jul 28, 12:01PM CDT
SmarTrend identified an Uptrend for Bio-Reference Labs (NASDAQ:BRLI) on March 24th, 2015 at $35.80. In approximately 4 months, Bio-Reference Labs has returned 25.90% as of today's recent price of $45.06.
BRLI: 34.69 (+0.08)
The Market for Prenatal, Newborn and Carrier Genetic Testing 2015
M2 - Fri Jul 24, 4:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h7ccfb/the_market_for) has announced the addition of the "The Market for Prenatal, Newborn and Carrier Genetic Testing" report to their offering. The Market for Prenatal, Newborn and Carrier Genetic Testing discusses the technologies and tests used in chromosomal analysis and in the diagnosis of inherited disorders and the detection of carriers of inherited diseases. The growing number of genetic tests has been made possible by advances in technology, including advances in chromosomal analysis - from traditional karyotyping to fluorescence in situ hybridization (FISH), and then to chromosomal microarrays and next generation sequencing. Detection of single gene mutations has been made possible with FISH and polymerase chain reaction (PCR) technology, and is moving into even new possibilities with sequencing based tests that can evaluate large numbers of genes simultaneously. The recent introduction of noninvasive prenatal testing (NIPT) has made it possible to perform prenatal screening of fetuses without the need for invasive procedures. The growing global genetic testing laboratory services market is discussed, including: - Carrier testing - Prenatal testing - Newborn screening - Neonatal/pediatric testing - Testing for adult onset genetic disorders The technologies used for newborn screening discussed in the report include: - Karyotyping - Fluorescence in situ Hybridization - Chromosomal Microarrays - Polymerase Chain Reaction and Other Nucleic Acid Amplification Technologies - DNA Sequencing - Mass Spectrometry - Conventional versus Non-Invasive Prenatal Testing Inherited disease testing was already a large market, but the potential for rapid growth has attracted companies and investors. The report highlights recent activities in this rapidly evolving market. Leading competitors and product developers are listed in the manufacturer profiles. The profiled companies include: Partial List - 23andMe, Inc. - AB SCIEX (A Danaher Corporation Company) - Abbott Laboratories - Affymetrix, Inc. - Agena Bioscience Inc. - Agilent Technologies Inc. - Ambry Genetics Corp. - ARUP Laboratories - Astra Biotech GmbH - Asuragen, Inc. - Athena Diagnostics, Inc. (A Quest Diagnostics Business) - AutoGenomics, Inc. - Berry Genomics Co., Ltd. - BGI-Shenzhen - Bio-Rad Laboratories, Inc. - Bio-Reference Laboratories, Inc. (BRLI) - Centogene AG - Chromsystems Instruments & Chemicals GmbH - Claritas Genomics, Inc. - Color Genomics, Inc. - CombiMatrix Corporation - Counsyl, Inc. - Courtagen Life Sciences, Inc. - GenapSys - Gene by Gene, Ltd. - Genection, Inc. (An Invivoscribe Company) - GeneDx - GenePeeks, Inc. - Genesis Genetics - Genetadi Biotech S.L. - Genetic Technologies Limited / Phenogen Sciences, Inc. (U.S. Division) - GenMark Diagnostics, Inc. - Genoma Group - Genomed AG - GenPath / GenPath Women's Health For more information visit http://www.researchandmarkets.com/research/h7...market_for
GNMK: 8.63 (+0.11), ABT: 42.30 (+0.28), AGMX: (), BRLI: 34.69 (+0.08), A: 46.99 (+0.01), CBMX: 2.97 (-0.08), AFFX: 14.01 (+0.02), ATHN: 123.13 (+0.70)
Uptrend Call Working As Bio-Reference Labs Stock Rises 23.6% (BRLI)
Comtex SmarTrend(R) - Tue Jul 21, 10:42AM CDT
SmarTrend identified an Uptrend for Bio-Reference Labs (NASDAQ:BRLI) on March 24th, 2015 at $35.80. In approximately 4 months, Bio-Reference Labs has returned 23.56% as of today's recent price of $44.23.
BRLI: 34.69 (+0.08)
Analyst Scanner on Medical Laboratories and Research Equities -- Thermo Fisher Scientific, Quest Diagnostics, Exact Sciences, VWR Corp., and Bio-Reference Laboratories
PR Newswire - Tue Jul 21, 8:05AM CDT
Equity Research Institute has initiated coverage on the following equities: Thermo Fisher Scientific Inc. (NYSE: TMO), Quest Diagnostics Inc. (NYSE: DGX), Exact Sciences Corporation (NASDAQ: EXAS), VWR Corporation (NASDAQ: VWR), and Bio-Reference Laboratories Inc. (NASDAQ: BRLI). Free research report on Thermo Fisher Scientific can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=TMO On Monday, July 20, 2015, the NASDAQ Composite ended at 5,218.86, up 0.17%, the Dow Jones Industrial Average advanced 0.08%, to finish the day at 18,100.41, and the S&P 500 closed at 2,128.28, up 0.08%. The losses were broad based as five out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
BRLI: 34.69 (+0.08), VWR: 27.75 (-0.16), TMO: 150.95 (-1.24), DGX: 82.36 (-0.46), EXAS: 18.19 (-0.28)
Research and Markets: Pharma Vital Signs: The Analyst's Perspective - June 2015 Issue
BusinessWire - Wed Jul 15, 7:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qv6c38/vital_signs_the) has announced the addition of the "Vital Signs - The Analyst's Perspective - June 2015 Issue" report to their offering.
BRLI: 34.69 (+0.08), OPK: 9.29 (+0.19)
Pharma Vital Signs: The Analyst's Perspective - June 2015 Issue
M2 - Wed Jul 15, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qs49hj/vital_signs_the) has announced the addition of the "Vital Signs - The Analyst's Perspective - June 2015 Issue" report to their offering. This issue of Vital Signs, released in July 2015, discusses Affmetrix's acquisition of Eureka Genomics, OPKO Health's acquisition of Bio-Reference Laboratories, CVS Health's acquisition of Target's in-store pharmacies and clinics, and Thermo Fisher Scientific's acquisition of Alfa Aesar. Affymetrix acquired all the assets of Eureka Genomics, including its high throughput crop and animal genotyping technology, for $15 million. Eureka's assays use next-generation sequencing (NGS), a rapidly growing technology utilized in various applications. As part of the acquisition, Affymetrix has also signed a multi-year contract to offer Eureka's technologies to Zoetis for use in animal genetics. Zoetis is a subsidiary of Pfizer and is the largest producer of medicine and vaccinations for pets and livestock. Molecular testing is a rapidly growing area in healthcare. The fields of application are now extending beyond life sciences and clinical diagnostics to other areas. Next-generation sequencing technologies are rapidly being employed in animal testing for testing pathogens. this is an emerging segment that requires a lot of trait management and traceability. Gene testing for animal health and cattle management has been relatively expensive, and technologies to facilitate broader genotyping of low-density traits, such as parentage, have been limited. Eureka Genomics is a developer of cost-effective high, medium, and low assays that use NGS technology for signal read out. these assays can enable the detection of several genetic markers that have high prevalence in crop and animal genomic testing. Eureka also provides NGS and genotyping services to government agencies, universities, research centers, and agriculture companies. Its assays can be applied to detection of copy number variation (CNV), methylation, and single nucleotide polymorphisms (SNPs). the information is compatible with any dNA or rNA from any organism, despite the incompleteness of genome information. this makes the technology very unique and powerful, answering several questions by combining discriminatory power of hybridization and ligation. Furthermore, Eureka's assays are NGS instrument agnostic and can be easily adapted to any modifications made in the instruments, such as upgrading, data generation, or even change of instrument. Affymetrix has a strong presence with its product offerings for microarrays, polymerase chain reaction (PCR), flow cytometry, and sample purification. Given its market leadership in the microarray market, a substantial amount of customers use Affymetrix's products. the area of animal testing and agrigenomics is not new to Affymetrix, as it sells its Axiom Genotyping solutions in this space. reports also reveal that Affymetrix's customers have demanded a low-cost, effective solution focused on genetic variant panels for high-volume testing. The effect of the symbiotic relationship can be sensed over time. through this acquisition, Affymetrix can extend its business to a new business unit catering to the agrigenomics space. As a result, its customers can now support more applications, and Affymetrix can also serve new customers with a greater bandwidth of solutions. The company has also employed Eureka's assays and technologies with Zoetis, which is one of the largest animal health companies. The acquisition has already bolstered Affymetrix's presence in the cattle and animal health sector. In looking at Affymetrix's acquisitions in the past, the company made its last acquisition in 2012, acquiring eBioscience to expand into flow cytometry antibodies and strengthen its offerings in the reagent segment. Strengthening its current product line and expanding its customer base has been Affymetrix's long-term strategy since 2008. Key Topics Covered: 1. Affymetrix Acquires Eureka Genomics for $15 Million 2. OPKO Health, Inc. Acquires Bio-Reference Laboratories, Inc. for $1.47 Billion in Stock 3. Target Signs the Dotted Line Facilitating CVS Health to Acquire its In-store Pharmacies and Clinics 4. Thermo Fisher Scientific Acquires Alfa Aesar, Further Consolidating Life Science Chemicals Market Companies Mentioned - Affmetrix - Alfa Aesar - Axiom Genotype - Bio-Reference Laboratories - CVS Health - Eureka Genomics - OPKO Health, Inc. - Pfizer - Target - Thermo Fisher Scientific - Zoetis For more information visit http://www.researchandmarkets.com/research/qs..._signs_the
BRLI: 34.69 (+0.08), OPK: 9.29 (+0.19)
